Article Precision medicine

The End of “Undruggable?”: Why RASolute-302 May Mark the Beginning of the Pan-RAS Era

The phase 3 RASolute-302 trial marks a potential turning point in oncology, demonstrating that pan-RAS inhibition with daraxonrasib may significantly improve survival in metastatic pancreatic cancer.…

By Corey Wise

Article Precision medicine

Minimal Residual Disease in Oncology

Minimal residual disease (MRD) testing has become one of the most important advances in cancer care over the past twenty years. It can find very small…

By Melissa Pozotrigo

Article Precision medicine

The Rising Complexity of Genetic and Molecular Testing in Oncology: Three Challenges Health Plans Can’t Ignore

Genetic and molecular testing is transforming oncology care, but it is also introducing a new layer of complexity, cost, and clinical risk for health plans.